Yeah, the AR-1001, also known as mirodenafil, was used in a Phase II clinical trial of patients with mild to moderate Alzheimer’s disease. As a Phase II trial, it’s mainly to look at safety and tolerability, but there were clinical endpoints also included in this smaller clinical trial of just over 200 participants. There were two doses of meridenafil that were used and compared to placebo...
Yeah, the AR-1001, also known as mirodenafil, was used in a Phase II clinical trial of patients with mild to moderate Alzheimer’s disease. As a Phase II trial, it’s mainly to look at safety and tolerability, but there were clinical endpoints also included in this smaller clinical trial of just over 200 participants. There were two doses of meridenafil that were used and compared to placebo. So we had three options in a one-to-one-to-one ratio of those who participated in the clinical trial. Now, it was found to be relatively safe, only one serious adverse event related to the drug of syncope, meaning sort of fainting. And then in terms of endpoints, clinical endpoints, unfortunately, there was no difference in the treatment groups, either treatment groups compared to placebo in a lot of these clinical measures. But post-hoc analysis, so retrospective analysis, looking at some of the biomarkers in those who got the high dose of the drug found reduction in P-Tau-181, P-Tau-217, in addition to reduction in GFAP, glial fibrillary acidic protein, sort of a marker of inflammation. So that was really exciting in terms of, hey, maybe this drug actually works on some of the biomarkers and downstream markers of what we might see and expect in Alzheimer’s disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
